此内容来自:xinyabo体育app

2014年全美研究团队:管理护理,第2号:Joshua Raskin

    <2014年全美研究团队 Joshua Raskinbarclaysfirtt-Place外观:1

    总出现:3

    团队首次亮相:2002年

    巴克莱分析师约书亚罗斯顿在该名册上的第2名和卫生保健设施列表的亚军重复。他预测美国管理层的股票将继续优于9月中旬至9月中旬的年度日期,而该国广阔的市场上涨7.3%。Preferred names in the group include Aetna in Hartford, Connecticut, and St. Louis’s Centene Corp. Aetna’s May 2013 acquisition of Bethesda, Maryland–based Coventry Health Care “continues to move along ahead of pace, and additional synergies are pushing guidance higher,” notes Raskin. His $95 price objective for the stock represents a 15.7 percent upside to their value in mid-September. As for Centene, Raskin highlights the company’s strong second-quarter results and management’s modest boost to guidance for 2014. “Most important, in this phase of above-average industry growth, the top line continues to exceed our estimates, and revenue guidance is up another 5 percent,” he notes. Centene traded at $77.21 in mid-September, and he forecasts a rise to $96. “Josh works harder than anyone to condense all of the health care service company regulatory filings into information I can use to make investment decisions,” reports one admirer. “He also delivers information on key trends, earnings releases and company announcements faster than anyone else on the Street, making it easier to come to timely investment decisions that can make or save money.”